Genomictree Inc. (228760.KQ)
KRW 23550.0
(3.06%)
KRW 23550.0
(3.06%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.26 Billion KRW | -24.78% |
| 2022 | 21.62 Billion KRW | 86.52% |
| 2021 | 11.59 Billion KRW | -1.7% |
| 2020 | 11.79 Billion KRW | 23.1% |
| 2019 | 9.57 Billion KRW | 254.47% |
| 2018 | 2.7 Billion KRW | 44.09% |
| 2017 | 1.87 Billion KRW | 44.29% |
| 2016 | 1.29 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.2 Billion KRW | 22.09% |
| 2024 Q2 | 3.63 Billion KRW | 13.37% |
| 2023 Q1 | 3.65 Billion KRW | -38.69% |
| 2023 Q4 | 2.62 Billion KRW | -12.87% |
| 2023 FY | 16.26 Billion KRW | -24.78% |
| 2023 Q2 | 6.97 Billion KRW | 90.78% |
| 2023 Q3 | 3.01 Billion KRW | -56.8% |
| 2022 Q2 | 3.25 Billion KRW | -62.21% |
| 2022 FY | 21.62 Billion KRW | 86.52% |
| 2022 Q4 | 5.96 Billion KRW | 56.91% |
| 2022 Q3 | 3.79 Billion KRW | 16.82% |
| 2022 Q1 | 8.6 Billion KRW | 153.75% |
| 2021 FY | 11.59 Billion KRW | -1.7% |
| 2021 Q3 | 2.6 Billion KRW | 0.0% |
| 2021 Q4 | 3.39 Billion KRW | 30.28% |
| 2020 FY | 11.79 Billion KRW | 23.1% |
| 2019 FY | 9.57 Billion KRW | 254.47% |
| 2018 FY | 2.7 Billion KRW | 44.09% |
| 2017 FY | 1.87 Billion KRW | 44.29% |
| 2016 FY | 1.29 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 85.212% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -107.306% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 70.786% |
| Bioneer Corporation | 204.55 Billion KRW | 92.049% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -110.135% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 75.098% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | 49.753% |
| Helixmith Co., Ltd | 37.36 Billion KRW | 56.473% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 94.312% |
| Medy-Tox Inc. | 110.88 Billion KRW | 85.332% |
| Peptron, Inc. | 16.65 Billion KRW | 2.352% |
| Amicogen, Inc. | 52.82 Billion KRW | 69.209% |
| Genexine, Inc. | 41.62 Billion KRW | 60.928% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -0.609% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 83.507% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 60.267% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 81.815% |
| SillaJen, Inc. | 5.11 Billion KRW | -218.155% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | 36.625% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | 53.858% |
| MedPacto, Inc. | 26.91 Billion KRW | 39.579% |
| D&D Pharmatech | 32.16 Billion KRW | 49.43% |
| EASY BIO,Inc. | 29.67 Billion KRW | 45.184% |
| GI Innovation, Inc. | 57.59 Billion KRW | 71.759% |